Adapting the story: Russian narrative adaptation during Sweden’s NATO accession
Media, War & Conflict · 20.11.2026
DOI: 10.1177/17506352261501360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Media, War & Conflict, online erschienen am 20.11.2026. Verfasst von Linus Wahlberg. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Previous research has shown how authoritarian states project antagonistic narration internationally, identified its disruptive capacities, and uncovered recurring antagonistic narrative strategies . Yet, little is known about how narrative strategies adapt as the strategic environment shifts. This article examines how Russia adapted its narratives during Sweden’s NATO accession by applying and extending an analytical framework highlighting three strategies in Russian antagonistic narration: “suppression,” “destruction,” and “direction” (SDD). Empirically, it shows how Russia adapted its antagonistic narrative strategies to changing “leverage points”—political decisions still open to influence—across the accession. The paper interprets the pattern of adaptation and suggests a mechanism of “leverage-contingent narrative recalibration”: when a threshold closes one “leverage point” of political influence, antagonistic narration recalibrates its dominant strategy toward the leverage point that remains available, while maintaining the underlying strategic objective.
Zitieren
APA
Wahlberg, L. (2026). Adapting the story: Russian narrative adaptation during Sweden’s NATO accession. Media, War & Conflict. https://doi.org/10.1177/17506352261501360
Vancouver
Wahlberg L. Adapting the story: Russian narrative adaptation during Sweden’s NATO accession. Media, War & Conflict. 2026. doi:10.1177/17506352261501360
BibTeX
@article{Wahlberg2026,
author = {Wahlberg, Linus},
title = {Adapting the story: Russian narrative adaptation during Sweden’s NATO accession},
journal = {Media, War & Conflict},
year = {2026},
doi = {10.1177/17506352261501360}
}
EUVIMED